What Thyreos does

Thyreos Inc. is a pre-revenue biotech startup founded in 2017 and headquartered in Lincoln, Nebraska, developing prophylactic vaccines for neuroinvasive herpesvirus infections. The company's core asset is the proprietary R2 vaccine platform, a recombinant herpesvirus technology that selectively eliminates the R2 component (region 2 of the pUL37 tegument protein) responsible for nervous system invasion. This produces "neutered" vaccine candidates that elicit robust immune responses without infecting neural tissue, removing the need for adjuvants or repeat vaccinations. The platform is applicable to all neuroinvasive alpha-herpesviruses, including HSV-1, HSV-2, varicella zoster virus, and pseudorabies virus, with peer-reviewed proof-of-concept demonstrated in guinea pig and pig models.

Thyreos pursues a dual-market strategy. The primary near-term focus is animal health, specifically a USDA SBIR-funded vaccine for cattle targeting Infectious Bovine Rhinotracheitis (IBR), with the secondary longer-term opportunity in human health applications such as HSV-2 (genital herpes), shingles, and vaccine vector development. The company is academic-spinout in structure, co-founded by three principal investigators — Dr. Ekaterina Heldwein (Tufts), Dr. Gary Pickard (University of Nebraska-Lincoln), and Dr. Gregory Smith (Northwestern) — with Eric Zeece serving as CEO to drive commercialization.

The business model relies on non-dilutive grant funding (USDA SBIR) and state-level venture capital (Invest Nebraska) during the pre-revenue R&D phase, with planned future monetization through vaccine product sales and technology licensing to pharmaceutical partners. Co-founder Smith's genetic tools are already under license by multiple pharmaceutical companies, establishing an early channel precedent. The company employs 1-10 people, has filed no commercial patents to date, and has no disclosed revenue, ARR, or product approvals.

Name

Thyreos

Legal name

Thyreos Inc

Website

https://thyreosvaccines.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Thyreos is a pre-revenue biotech developing prophylactic vaccines for neuroinvasive herpesvirus infections using its proprietary R2 platform, which removes the viral protein region responsible for nervous system invasion. The company initially targets cattle IBR via USDA funding and plans to expand into human HSV and shingles vaccines.

Ownership category

akta.pro rank

Product category

Animal Health Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

akta.pro secondary industries

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Veterinary Vaccines (Biologics) (HLAMAEAL), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Herpesvirus vaccines
• Animal health vaccines
• Prophylactic vaccines
• Recombinant vaccine platform
• Biotechnology research

Headquarters

HQ city

Lincoln

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Vaccine Development and Licensing: Pre-revenue biotech startup developing proprietary herpesvirus vaccines. Revenue expected through vaccine product sales and technology licensing to pharmaceutical companies. R&D funded by SBIR grants with commercial potential in animal health and human health markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Thyreos develops prophylactic vaccines for neuroinvasive herpesvirus infections using its proprietary R2 recombinant vaccine platform. The platform selectively removes neuroinvasive potential by eliminating the R2 component of the pUL37 tegument protein, producing vaccines that elicit robust immune responses without infecting the nervous system. Products target both animal health (cattle IBR vaccine) and human health (HSV-1, HSV-2, varicella zoster) markets, plus recombinant vaccine vectors.

Product overview

Thyreos develops herpesvirus vaccines and vaccine vectors for the animal health and human health markets. The company's core offering is the R2 Vaccine Platform—a recombinant herpesvirus technology that elicits robust immune responses without infecting the nervous system. The R2 Platform serves as the foundation for the Herpesvirus Vaccines product family, which includes prophylactic vaccines targeting neuroinvasive herpesviruses such as HSV-1, HSV-2, pseudorabies virus, and varicella zoster virus. Additionally, Vaccine Vectors leverage this platform technology for broader health applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Thyreos R2 Vaccine Platform A proprietary recombinant herpesvirus platform that elicits robust immune responses without infecting the nervous system. The platform selectively removes neuroinvasive potential by eliminating the R2 component of the pUL37 tegument protein, creating non-neuroinvasive vaccines that protect the nervous system while fortifying the immune system. Used as the foundational technology for all Thyreos vaccine products targeting animal and human health markets.
• Herpesvirus Vaccine for Cattle (IBR) Prophylactic vaccine for cattle targeting Infectious Bovine Rhinotracheitis (IBR) caused by bovine herpesvirus. Built on the R2 platform, it enhances vaccine efficacy and safety by protecting the nervous system from herpesvirus invasion, eliminates the need for adjuvants and repeat vaccinations, and reduces costs for cattle producers.
• Vaccine Vectors Recombinant herpesvirus vectors derived from the R2 platform for use in animal health and human health applications, leveraging the platform's ability to generate robust immune responses without neuroinvasive properties.

Quantifiable outcome

• Protection from genital HSV-2 infections demonstrated in guinea pig model
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Emerging players

• BioNTech: mRNA-based vaccine developer that has publicly explored HSV and shingles vaccine candidates using a different (mRNA) technology platform. Comparable as a competing developer of next-generation herpesvirus vaccines targeting the same human indications Thyreos may pursue.
• Genocea Biosciences: Was a clinical-stage biotech developing GEN-003, an HSV-2 therapeutic vaccine. Comparable as a former direct peer in the HSV vaccine space that illustrates the high-risk/high-cost pathway of bringing a herpesvirus vaccine through clinical development.
• CaroGen Corporation: Emerging vaccine developer using a proprietary virus-like vesicle (VLV) platform for herpesvirus and hepatitis B vaccines. Comparable as a small-cap herpesvirus vaccine developer pursuing similar prophylactic indications to Thyreos.
• Curevo Vaccine: Clinical-stage biotech developing non-mRNA subunit shingles (VZV) vaccines designed to be non-adjuvanted. Comparable because it targets the same herpesvirus indication (VZV/shingles) with an alternative adjuvanted/no-adjuvant product profile similar to Thyreos's stated benefits.

Broad incumbents

• Merck Animal Health: Major veterinary vaccine manufacturer with IBR and bovine respiratory disease products. Comparable as a competing supplier in the cattle herpesvirus vaccine market and a likely candidate to license or partner with Thyreos for distribution.
• Moderna: Major mRNA vaccine platform company developing candidates against herpesviruses (VZV/HSV). Comparable because it represents an alternative platform approach to the same human herpesvirus indications Thyreos targets with its R2 platform.
• GSK (Shingrix franchise): Sells Shingrix, the dominant shingles (VZV) vaccine. Comparable because it operates in the human herpesvirus vaccine market that Thyreos's R2 platform could enter for VZV (and potentially other herpesviruses).
• Zoetis: World's largest animal health company, with a broad livestock and companion animal vaccine portfolio including bovine herpesvirus vaccines. Comparable because it operates in the same veterinary vaccine category with established distribution and USDA-licensed products that Thyreos's IBR candidate would compete against or partner with.
• Boehringer Ingelheim Animal Health: Global animal health leader and incumbent in the cattle IBR vaccine market (e.g., Bovilis IBR). Comparable because it sells competing veterinary herpesvirus vaccines for livestock and pursues vaccine innovation in the same bovine respiratory disease segment Thyreos targets.

Direct peers

• Rational Vaccines: Clinical-stage biotech developing live-attenuated HSV vaccines for therapeutic and prophylactic use. Comparable because it directly competes in the herpesvirus vaccine space with a different attenuation strategy, sharing the same target indications (HSV-1/HSV-2) as Thyreos.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/thyreos

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thyreos